HCPCS Level II · Outpatient PPS (temporary codes)
C9098Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Terminated 09/30/2022
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About C9098
C9098 is an HCPCS Level II code in the C series (outpatient PPS (temporary codes)), describing ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.
It was added to HCPCS effective 07/01/2022, and its current record took effect 10/01/2022.
It was terminated on 09/30/2022 and can't be billed for later dates of service.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Ciltacabtagene car pos t
- Date added
- 07/01/2022
- Action effective
- 10/01/2022
- Termination date
- 09/30/2022
- BETOS
- O1D
Related C90xx codes
Common questions about C9098
Is HCPCS C9098 still valid?
- No. C9098 was terminated on 09/30/2022.
Does Medicare cover C9098?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.